Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7388944 | Value in Health | 2018 | 11 Pages |
Abstract
In G-BA appraisals, oncology medicines with crossover received better additional benefit ratings, but were assigned lower evidence levels, than those without. The five medicines with crossover after progression were assigned lower evidence levels than the six medicines with crossover after demonstration of superior OS, indicating that the way in which crossover is implemented may be one factor influencing the assignment of evidence levels by the G-BA.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Georg MD, Thomas R. MSc, Volker E. PhD, Charalabos-Markos MPH, Christof MD, Sonja Mariotti PhD, Miriam PhD, Jörg MD, MPH, MBA,